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Abstract
Background: Ovarian cancer is the leading cause of death worldwide among gynecologic malignancies. The recent
approval of inhibitors of poly (ADP-ribose) polymerase (iPARP) in the treatment of ovarian cancer in the presence of a
BRCA1/2 mutation has sparked the analysis of women with such diagnosis, which can further benefit from the detection
of carriers in the family. Germline sequence and large rearrangements for BRCA1/2 were tested in 398 consecutive
epithelial ovarian cancer (EOC) patients.
The aim of this study was to identify the frequency and spectrum of germline BRCA1/2 pathogenic alterations in a
cohort of patients with ovarian serous carcinoma, with a view to adequately selecting patients for prevention through
family counseling and correlating this frequency with platinum sensitivity as a guidance to identify patients eligible for
iPARP in our population.
Results: A total of 96 patients carried a pathogenic germline mutation, accounting for an overall 24.1% mutation
incidence. Among mutation carriers, BRCA1 showed 62.5% incidence, BRCA2 rendered 36.5%, and one patient
exhibited a mutation in both genes. Three pathogenic mutations were recurrent mutations detected five, three,
and four times and represented 12.5% of the mutated samples. Worth highlighting, a 50% mutation incidence
was detected when breast and ovarian cancer coexisted in the same patient. Novel mutations amounted to 9.4%
of the total mutations, as compared to 4.7% in breast cancer. Forty out of 60 BRCA1 mutations were beyond the
ovarian cancer cluster region (OCCR), in stark contrast with 22 out of 36 BRCA2 mutations being inside the OCCR.
Taken together, germline BRCA1/2 mutations in EOC patients showed a distinct mutational spectrum compared
to our previously published data on breast cancer patients.
Conclusions: In sum, our study provides novel data on ovarian BRCA1/2 mutation prevalence worldwide, enhances
adequate patient selection for family counseling and prevention, and sheds light on the benefits of iPARP treatment.
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Background
Ovarian cancer is the leading cause of death worldwide
among gynecologic malignancies. Argentina exhibits mid-
high rates, and, in 2016, the National Cancer Institute,
Ministry of Health (Instituto Nacional del Cáncer, INC,
Ministerio de Salud de la Nación), reported a total of 2274
ovarian cancer cases out of a total of 60,209 women
cancer cases, which represents 3.8% (Argentina, 2016,
SIVER-Ca, INC, Ministerio de Salud de la Nación).
Genetic testing for BRCA1/2 mutation carriers proves
critical to clinical decisions, as more than 90% of the
cases of epithelial ovarian cancer (EOC) are diagnosed
with bulky intra-abdominal disease or distant metastases
[1]. The importance of BRCA1/2 mutation screening in
ovarian cancer patients has been further underscored by
recent findings showing that mutation carriers have in-
creased sensitivity to inhibitors of poly (ADP-ribose) poly-
merase (PARP) [2, 3]. In fact, PARP inhibitors (iPARP)
have recently been approved for the treatment of ad-
vanced ovarian cancer patients carrying either germline or
somatic mutations in BRCA1/2 genes [4]. Moreover,
BRCA1/2 mutation status has been shown to predict re-
sponse to iPARP. Individuals with germline BRCA1/2 al-
terations treated with iPARP have a significant increase in
progression-free survival compared with patients with
wild-type BRCA1/2 [3, 5].
The reported prevalence of BRCA1/2 mutations in pa-
tients with ovarian cancer varies across different studies
and ethnic populations. A report interpreting the results
of 14 studies from eight Western countries, summarized
in a meta-analysis, has shown the overall incidence of
germline mutations to be 18.0% for BRCA1 and 6.9%
for BRCA2, although this incidence ranges between 3.4
and 47% for BRCA1 and between 1 and 12% for BRCA2
[6] when considering specific populations. Reports from
Asia have revealed the following figures: in South Korea
[7], only one pathogenic mutation was found in the
BRCA1 gene among 37 EOC patients; a Japanese study
[8] found 5.3% cases with germline mutations in
BRCA1 and 7.4% in BRCA2; in Hong Kong [9], the
publication of a series of 60 ovarian cancer patients an-
alyzed for the whole coding region of BRCA1 but only
the exon 11 of BRCA2 rendered 11.3% and 2.1% pa-
tients carrying a mutation, respectively, including the
c.1081delG in BRCA1, which seemed to be a founder
mutation from Southern Chinese populations, and two
recurrent mutations, i.e., c.2371-2372delTG in BRCA1
and c.3337C>T in BRCA2; finally, in the Chinese popu-
lation [10], the rate of mutation carriers among patients
was reported to be 16.7%, with the description of a pre-
sumably very frequent non-founder mutation, i.e.
c.5470_5477del8 in BRCA1, and the conclusion that the
spectrum of BRCA1/2 mutations greatly differs from
that described in Western studies.
Relatively few studies have been reported on South
American populations, and the most readily available re-
sults are based on small-size cohorts. A Colombian study
has reported 100 patients with ovarian cancer diagnosis
and 15% of mutation detection—13% in BRCA1 and 2% in
BRCA2—including an 11% accounting for a founder mu-
tation [11]. A review of Latin American and Caribbean
studies summarizes breast/ovarian cancer cases from a
few countries. However, only a limited number of studies
used full sequencing analysis and ovarian cancer was not
clearly disclosed, which prevented the review from reach-
ing conclusions [12].
To gain a more complete insight into the prevalence
of BRCA1/2 mutations in EOC patients from Argentina,
we performed a cohort study of 398 unselected consecu-
tive EOC patients for BRCA1/2 mutation screening
using the next-generation sequencing (NGS) approach
and multiplex ligation-dependent probe amplification
(MLPA) for large rearrangements.
The aim of this study was to identify the frequency and
spectrum of germline BRCA1/2 pathogenic alterations in a
cohort of patients with ovarian serous carcinoma, with a
view to adequately selecting patients for prevention through
family counseling and correlating this frequency with plat-
inum sensitivity as a guidance to identify patients eligible
for iPARP in our population. In addition, and considering
similarities in the population analyzed, this study presents a
comparison with results previously published by our group
[13] on BRCA1/2 mutations in breast cancer patients.
Methods
Study subjects
Subjects were selected among women diagnosed with epi-
thelial ovarian cancer and referred to Centro de Educación
Médica e Investigaciones Clínicas (CEMIC) for genetic
testing from January 2014 to June 2017. A total of 398 pa-
tients were included in the study, 299 of whom were se-
lected by the inclusion criteria required for treatment with
iPARP (high-grade ovarian serous carcinoma, relapsed,
second-line platinum-sensitive). Routine procedure in-
cluded signing a written informed consent to genetic test-
ing (including anonymized disclosure of the data) from
each patient, approved by the Ethics Committee from
CEMIC, and a Pretest Counseling for Susceptibility Test-
ing (purpose of testing), as described in the American Soci-
ety of Clinical Oncology Policy Statement Update [14].
Subjects enrolled in this study showed a mean age at
diagnosis of 53.5 ± 12 years, within a range of 18 to 84 years
of age. Eligible patients included women with newly diag-
nosed, histologically confirmed, or chemotherapy-treated
serous ovarian cancer, regardless of chemotherapy line.
Although data on family history (FH) were collected as
part of the study, recruitment was independent of FH
conditions.
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BRCA testing
Genomic DNA of the 398 blood samples was isolated
by MagNA Pure® LC instrument with total DNA isola-
tion kit I (Roche Diagnostics). Analysis of BRCA1/2
genes included complete sequencing and study of large
rearrangements.
The Ion AmpliSeqBRCA1/2 community panel was
used for the targeted NGS, as it allows to amplify the en-
tire coding sequences of BRCA1 and BRCA2, including
20–50 bases of adjacent intronic sequence of each exon.
Sequencing of the amplified regions was performed with
the next-generation platform Personal Genome Machine®
System. As a control, the STR variants of every sample
were previously traced and intra NGS [15] was used to en-
sure the identification of the sample and avoid possible
processing. The few codifying sequences with low readings
were analyzed by Sanger reaction in order to reach 100%
coverage.
The raw signal data and the sequence reads were proc-
essed with Ion Torrent Suite software (Thermo Fisher
Scientific) on a Torrent server. The pipeline included
signaling processing, base calling, quality score assign-
ment, adapter trimming, PCR duplicate removal, read
alignment to the reference human genome 19, quality
control of mapping quality, coverage analysis, and vari-
ant calling. Coverage analysis used plug-in software in
the Torrent server. The variant caller parameter setting
was germline PGM (Life Technologies).
After data analysis, single-nucleotide variants, inser-
tions, deletions, and splice site alternations were regis-
tered, and all variants detected were reported. Sanger
DNA sequencing was used to confirm all clinically rele-
vant variants detected (classes 3, 4, and 5) using the spe-
cific gene primers. Clinical significance was determined
according to the report in the reference databases
(ClinVar [16], LOVD 3.0 [17], UMD [18]—last access
December 29, 2017). For missense mutations not re-
ported or reported with uncertain clinical significance
(VUS), in silico programs were used to predict the change
in protein function using software Align-GVGD, SIFT,
and Mutations Taster.
Large rearrangements were measured by MLPA using
SALSA MLPA Probemix P002-D1 and P045-B3 pro-
vided by MRC-Holland, and Coffalyser.net software was
used for data analysis.
In a preliminary analysis for a panel of genes, 30 samples
were exome sequenced and then filtered for the following:
ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MSH2,
MLH1, MSH6, PMS2, EPCAM, NBN, NF1, PALB2, PTEN,
RAD51C, RAD51D, STK11, and TP53. Full exonic ± 20
bases of adjacent intronic sequence for each gene were as-
sured. These genes were selected according to the genes
listed in the NCCN guidelines (Genetic/Familial High-Risk
Assessment: Breast and Ovarian—Version 2.2017), for
which there are risk and management recommendations of
patients with a pathogenic mutation. In other words, these
actionable genes allow clinical measures such as monitor-
ing, treatment, counseling, and prevention for both the pro-
bands and their families.
We routinely share our genetic variants and collected at
Leiden Open Variation Database (Chapter for Argentina)
[19]. In the case of the novel variants, the registration
numbers of each of the variants in the LOVD database
[17] are shown in Table 2.
Genetic variant classification
The novel variants were classified according to the rec-
ommendation guidelines of the American College of
Medical and Genomics (ACMG) [20]. As they corres-
pond to variants not reported in the population and dis-
ease database all comply with the PM2 criteria of the
ACMG Guidelines, this is a criterion of moderate patho-
genicity. According to this:
Probably pathogenic mutations were defined as follows:
1. Nonsense and frameshift variants that generate a
premature stop codon, except for the variants that
generate a premature stop codon after codon 3326
in the BRCA2 gene (criterion PVS1 of the ACMG
guidelines)
2. Splice site variants that are found in intronic or
exonic variant in the exon-intron border (criterion
PVS1 of the ACMG guidelines)
Variants of uncertain clinical significance (VUS) were
defined as follows:
1. Missense variants where multiple lines of
computational evidence support to deleterious
effect on the gene or gene product or no impact
on gene or gene product (criteria PP3 and BP4
respectively of ACMG guidelines)
2. Synonymous (silent) variant for which splicing
prediction algorithms predict no impact to the
splice consensus sequence nor the creation of a
new splice site and the nucleotide is not highly
conserved (criterion BP7 ACMG guidelines)
3. Intronic variants distant from the intron-exon
boundary
Results
The sequencing of BRCA1/2 in 398 consecutive EOC
patients, including 299 patients selected for iPARP treat-
ment, rendered a total of 96 patients carrying a pathogenic
germline mutation. These cases are listed in Additional file 1,
which indicates patients selected for iPARP treatment in
italics and patients with novel mutations in bold. Overall
mutation incidence amounted to 24.1% (n = 398), while
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mutation incidence among patients selected for iPARP
treatment was 20.7% (n = 299) and mutation incidence
among non-iPARP-selected patients was 34.3% (n = 99).
The mutations found were as follows: 60 in BRCA1
(62.5%), 35 in BRCA2 (36.5%), and 1 in both genes (1%)
(Table 1). The mean age of diagnosis for the patients carry-
ing a mutation was 53.7 years, which was non-statistically
different from 54.3 years in the non-detected-mutation
group. The low end of the age range among patients with a
non-detected mutation, as well as among patients with
both breast and ovary cancer diagnosis was 31 years of age,
much higher than that of the mutation-carrying group at
18 years (Table 1). Remarkably, the patients diagnosed with
both cancers showed a 50% rate of mutation detection
(Table 1), again with similar distribution in both genes: 69%
detected in BRCA1, 27.6% in BRCA2, and 3.4% in both
genes.
Key to validating our population detection methods
and interpretation, only 3.38% variants were found of
unknown significance (VUS). Out of the total number of
mutations detected, nine were found to be novel dele-
terious mutations (9.4%), three of them in BRCA1 and
six in BRCA2, as listed in Table 2. Of note, BRCA1 mu-
tation c.3578_3759delCT has been previously described
by our group in an unrelated patient [21], although this
patient had breast cancer diagnosed at 31 years; BRCA2
mutation c.7805+2_7805+3delTA has also been already
described [13] but is included now as belonging to an
ovary cancer patient. Novel intronic variants detected to
be yet classified were c.670+31A>C, c.4357+22C>T, c.80
+52T>A, and c.516+3A>T.
Regarding recurrent pathogenic mutations, present in
3 or more patients each, 2 were detected in BRCA1 and
1 in BRCA2, including 12 patients among mutation
carriers (12.5%) (Table 3). These recurrent mutations
were c.4964_4982del19 and c.5266dupC in BRCA1 and
c.5351dupA in BRCA2, with five, three, and four detec-
tions, respectively.
The FH group—understood as having at least 1 relative
developing breast and/or ovarian cancer among first- or
second-degree relatives—accounted for 158 cases, among
which 55 rendered mutations (34.8%), including the pa-
tient with a mutation in both genes. In turn, the non-FH
group included 105 patients, 10 of whom were mutation
carriers (9.5%). No FH records were available for the
remaining 135 patients, 31 of whom revealed a mutation
(23.0%) (Table 4).
Regarding the spectrum of mutations along the genes
(Fig. 1), 40 out of 60 mutations detected in BRCA1
were located outside the ovarian cancer cluster region
(OCCR), in contrast with the findings for BRCA2, in
which 22 out of 36 were located inside the OCCR. In
the case of the patient carrying a mutation in the two
genes, both mutations were outside the OCCR. These
mutations were c.-19-?_80+?del and c.1909+1G>A for
BRCA1 and BRCA2, respectively (Additional file 1).
Discussion
In the current study, we have assessed the BRCA1/2 mu-
tation status in 398 EOC patients with two main goals:
the benefits of detecting hereditary breast/ovarian cancer
syndrome for prevention and the possibility of selecting
patients for treatment with iPARP. Results showed most
mutations to be found in the BRCA1 gene, reinforcing
once again the well-established association of ovary can-
cer and a mutation in BRCA1. In our series, however,
most of the mutations were outside the region of OCCR
of BRCA1, even as the most recent and detailed publica-
tion [22] reinforcing the necessity of reporting regional
genetic variants [19] and depositing genetic variants in
open access databases. The apparent differences with the
reported data [22] may very likely due to that no data
was included from South America (or may be very little
hidden in one of the categories); it is important to re-
mark that the Hispanic demographic group in this very
wide population analysis refers to a migration denomin-
ation in the USA and does not reflect South America
and specifically, our country [13].
Our assay is a comprehensive analysis, and our group
has vast experience in the regionality of the mutation spec-
tra in our patients [13, 23], which is reflected in the low
rate of 3.38% of VUS found in this series. The frequency of
mutations detected reached 24.1% (Table 1), a value closer
to the highest described in the literature [24, 25], lower
than other published results [8, 11, 26–31]. The 99 patients
not selected for iPARP treatment showed a striking pro-
portion of 34.3% mutation carriers, which may stem from
Table 1 BRCA1/2 sequence: summary of patients analyzed
Diagnosis n Age (range)a BRCA mutated (%) BRCA1 mutation
carriers (n)
BRCA2 mutation
carriers (n)
Non mutated (%)
EOC (total) 398 53.5 (18–84) 96 (24.1) 61b 36b 302 (75.9)
EOC and BC 58 56.5 (31–78) 29 (50.0) 21b 9b 29 (50.0)
The total number of patients analyzed was diagnosed with epithelial ovarian cancer (398). Among these, 58 patients also had a diagnosis of breast cancer
(EOC and BC)
EOC epithelial ovarian cancer, BC breast cancer, n number of cases
aAge at ovary cancer diagnosis
bOne of the patients with high-grade ovarian serous carcinoma and breast cancer had a mutation in both genes
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the fact that CEMIC is a reference center for hereditary
breast-ovary cancer patient analysis.
The worldwide age range of patients diagnosed with
EOC included in BRCA1/2 analyses [8, 11, 24–32] starts
around 30 years, with the exception of Colombia [11]
(16 years) and Argentina [13] (18 years). The lower-end
value of the range does not reflect the most frequent age
of diagnosis, as cases diagnosed in the patient’s sixties
are common, frequently with a mutation detected. This
is reflected in the similar mean age among all the results
published.
The high 50% rate of BRCA1/2 mutations detected in
58 patients with both cancers diagnosis (Table 1) is in line
with other studies on similar patients, although in smaller
numbers, such as the Japanese study with 3 cases [8], all
with a mutation detected. This is also in agreement with
our previous publication [13], in which we analyzed 14 pa-
tients with breast and ovary cancer, 11 of whom (78.6%)
bore a pathogenic mutation. Interestingly, seven mutations
were found in common with the current series of patients,
as follows: c.211A>G, c.1687C>T, c.1892dupT, c.5266dupC,
c.5468-1G>A, c.2808_2811delACAA, and c.5351dupA
(Additional file 1).
Worth pointing out, the gene spectrum (Fig. 1), in-
cluding data on the OCCR and the recurrent mutations
described (Table 3), does not visualize a panel or hot
spot of mutations to abbreviate the analysis of BRCA1/2
in our ovarian cancer population.
As an additional comment regarding FH (not included
in the criteria for the selection of patients), complemen-
tary data in the analysis of the results reveals large dif-
ferences obtained in mutation detection between the FH
and non-FH groups (34.8% vs 9.5%, p value = 0.000003,
significant at p < 0.05), which is in contrast with results
previously published [8]. This discrepancy may be ex-
plained by the larger number of patients studied in our re-
port (398 vs 95), and our higher rate of mutations
detected (24.1% vs 12.6%).
In turn, the following observations when comparing
the findings described for ovarian cancer patients with
our previous publication including a vast majority of
breast cancer patients [13] are as follows: (a) the rate of
Table 2 Novel variants in BRCA1 (NM_007294.3) and BRCA2 (NM_000059.3) genes detected in 398 probands with diagnosis of
epithelial ovarian cancer
Sample ID Gene Exon/intron Mutationa Predicted effectb MT CSc LOVD (genomic variant #)
BR1229 1B 11 c.2005dupA p.(Met669Asnfs*4) F LP 198881
BR2066 1B 11 c.3758_3759delCT p.(Ser1253*) F LP 196851
BR1037 1B 11 c.876_879delCACT p.(Thr293Lysfs*4) F LP 198751
BR1410 2B 11 c.2133C>A p.(Cys711*) N LP 202233
BR0986 2B 11 c.2860G>T p.(Glu954*) N LP 197664
BR0832 2B 11 c.4419delC p.(Asn1473Lysfs*6) F LP 201398
BR2072 2B 11 c.5253C>A p.(Tyr1751*) N LP 203562
BR1464 2B 14 c.7308delC p.(Asn2436Lysfs*31) F LP 206927
BR0495 2B 16i c.7805+2_7805+3delTA S LP 199222
BR1104 1B 11 c.2357T>C p.(Leu786Pro) M VUS 200898
BR0889 1B 11 c.3168C>T p.(Ser1056=) Syn VUS 200773
BR1061 1B 10i c.670+31A>C S VUS 196392
BR2063 1B 13i c.4357+22C>T S VUS 209404
BR1078 1B 2i c.80+52T>A S VUS 196406
BR0913 2B 6i c.516+3A>T S VUS 199956
MT mutation type, F frameshift, N nonsense, S splicing, M missense, Syn synonym, LP likely pathogenic, VUS variant of uncertain significance
aHGVS nomenclature at cDNA level
bHGVS nomenclature at protein level
cCS: interpretation and classification of the variants was carried out according to the recommendations of the ACMG guidelines
Table 3 Recurrent mutations in BRCA1/2 detected in 398
probands with epithelial ovarian cancer
Mutation/times detected Unrelated probands
(% of the total probands)
BRCA1
c.4964_4982del19 - p.(Ser1655Tyrfs*16)/5 5 (1.3)
c.5266dupC - p.(Gln1756Profs*74)/3 3 (0.8)
BRCA2
c.5351dupA - p.(Asn1784Lysfs*3)/4 4 (1.0)
Total recurrent 12 (3.1)
Total recurrent (12)/total mutated
(96) = 12.5%
–
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mutation detection was higher in ovarian cancer patients
with 24.1% vs breast cancer with 19.04% (p value =
0.035611, significant at p < 0.05); (b) the rate of novel
mutations showed a tendency: 9.4% for ovarian cancer
vs 4.7% for breast cancer. The population analyzed was
398 subjects for ovary cancer and 940 subjects for breast
cancer with a detection rate of 2.26% (9 out 398) and
0.85% (8 out 940) novel variants, respectively (p value =
0.035249, significant at p < 0.05); (c) the rate of recurrent
mutations was similar for both groups. Interestingly, the
spectrum of recurrent mutations for both genes was
spread along both genes.
A promising turn in the treatment of ovarian cancer
has been the attempt at repairing double-strand DNA
damage by homologous recombination repair pathway
(HRR) mechanisms. BRCA1 and BRCA2 are genes cen-
trally involved in this process, and mutations resulting in
damaged BRCA1 or BRCA2 proteins can lead to various
types of cancer such as breast, ovarian, or prostate can-
cer among the most closely associated. Even in the pres-
ence of a pathogenic mutation in BRCA, single-strand
break repair by non-homologous end joining is an alter-
native pathway to repair double-strand breaks, avoiding
cell death pathways like apoptosis. iPARP cause HRR
leading gene-deficient (including BRCA1/2) cancer cells
to die by apoptosis. This is known as “synthetic lethal-
ity,” a concept developed upon evidence on sensitivity of
BRCA1/2 defective cells to platinum salts [33, 34].
Preliminary results from exome analysis of a panel of
genes (see the “Methods” section) in 30 patients showed
the following non-BRCA1/2 mutations: in EPCAM,
c.412C>T p.(Arg138*), and coexisting mutations as fol-
lows: in MUTYH, c.1105delC - p.(Ala371Profs*23) and
in heterozygosis and RAD51D, c.1A>G p.(Met1Val). The
application of these results is still under consideration,
although the involvement of the RAD51D gene in the
HRR mechanism should be highlighted.
Conclusion
In sum, the strength of our study lies in the inclusion of
299 patients exclusively selected for treatment with
iPARP, plus an extra of 99 cases which could also benefit
from treatment, the use of thorough methodology and
Table 4 Family history in patients with epithelial ovarian cancer
Family history Number of probands
(% of total)
Patients with a mutation
detected (%)
Yesa 158 (39.7) 55 (34.8)
No 105 (26.4) 10 (9.5)
Not known 135 (33.9) 31 (23.0)
aYes: family history with at least 1 relative developing breast and/or ovarian
cancer among first- or second-degree relatives
Fig. 1 Schematic representation of the 96 BRCA1/2 pathogenic mutations detected in 398 patients with diagnosis of epithelial ovarian cancer
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knowledge of our population regional variants [13, 23],
as supported by the 3.38% of VUS found. The findings
reported here thus offer BRCA mutation carriers the
benefit of treatment possibilities and allow precise iden-
tification of hereditary breast-ovary disease and the pre-
ventive measures associated.
Additional file
Additional file 1: Pathogenic mutations in BRCA1 (NM_007294.3) and
BRCA2 (NM_000059.3) genes (n = 96) detected in 398 probands with
diagnosis of epithelial ovarian cancer. (DOCX 31 kb)
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